- The House Oversight and Government Reform Committee has launched an investigation into the cost of EpiPens, describing Mylan (NASDAQ:MYL) as having a "virtual monopoly" over the auto-injector market while profiting richly from its "unreasonable" pricing strategy.
- The letter asks Mylan executives to brief the committee by Sept. 6 and provide documents on its revenue, expenses and lobbying disclosures.